For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on sale of nonfinancial assets | - | 0 | 0 | 0 |
| Total revenues | 766,208 | 874,565 | 776,133 | 825,410 |
| Cost of sales | 194,999 | 275,709 | 140,085 | 150,090 |
| Research and development | 178,796 | 192,413 | 409,478 | 161,308 |
| Selling, general and administrative | 258,290 | 446,207 | 268,415 | 232,279 |
| Intangible asset amortization | 4,483 | 4,846 | 4,847 | 4,846 |
| Total operating expenses | 636,568 | 919,175 | 822,825 | 548,523 |
| Income from operations | 129,640 | -44,610 | -46,692 | 276,887 |
| Interest income | 22,560 | 19,210 | 17,854 | 18,827 |
| Interest expense | 14,958 | 2,778 | 2,579 | 2,679 |
| Other income (expense), net | 3,961 | 1,025 | 5,093 | 4,833 |
| Income before income taxes | 141,203 | -27,153 | -26,324 | 297,868 |
| Provision for income taxes | 35,676 | 19,420 | 4,420 | 57,336 |
| Net income | 105,527 | -46,573 | -30,744 | 240,532 |
| Basic EPS | 0.55 | -0.242 | -0.16 | 1.25 |
| Diluted EPS | 0.54 | -0.228 | -0.16 | 1.23 |
| Basic Average Shares | 192,497,000 | 192,242,000 | 192,032,000 | 191,907,000 |
| Diluted Average Shares | 197,671,000 | 203,979,000 | 192,032,000 | 197,091,000 |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)